This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buxton, E. C. Articles by Lane, N. E. Search for Related Content PubMed PubMed Citation Articles by Buxton, E. C. Articles by Lane, N. E.

Changes in Serum Receptor Activator of Nuclear Factor-B Ligand, Osteoprotegerin, and Interleukin-6 Levels in Patients with Glucocorticoid-Induced Osteoporosis Treated with Human Parathyroid Hormone (1–34)

Department of Medicine, University of California at San Francisco, San Francisco, California 94143

Address all correspondence and requests for reprints to: Dr. Nancy Lane, Division of Rheumatology, Box 0868, University of California at San Francisco, San Francisco, California 94143. E-mail: nelane{at}itsa.ucsf.edu.

Changes in biochemical markers of bone turnover following intermittent injections of human (h)PTH (1–34) suggest that bone formation is initially favored over bone resorption. hPTH (1–34) is also known to influence osteoclast maturation and activity through modulation of osteoblast-derived cytokines, such as receptor activator of nuclear factor-B ligand (RANKL), osteoprotegerin (OPG), IL-6, and IL-6 soluble receptor (IL-6sR). In this experiment, we investigated the changes in serum levels of soluble RANKL (sRANKL), OPG, IL-6, and IL-6sR in patients with glucocorticoid-induced osteoporosis treated with hPTH (1–34). Fifty-one postmenopausal women with glucocorticoid-induced osteoporosis were randomized to receive 12 months of 400 U hPTH (1–34) (40 µg) daily and standard hormone replacement therapy, or hormone replacement therapy alone. Serum levels of sRANKL, OPG, IL-6, and IL-6sR were measured at baseline, 1 month, and every 3 months thereafter for a total of 24 months. hPTH (1–34) caused a rapid and significant increase in sRANKL within 1 month, and the levels remained elevated throughout the duration of therapy. IL-6 and IL-6sR increased significantly within 1 month, but returned to baseline levels more rapidly. In contrast, OPG was mildly suppressed beginning 6 months after hPTH therapy. These data support the hypothesis that hPTH (1–34) initially stimulates osteoblast maturation and function, which in turn leads to osteoclast activation and a gradual rebalancing of bone formation and resorption.

This work was supported by National Institutes of Health Grants AR048841-01 and DK46661-07, the Rosalind Russell Arthritis Research Center, and by a Research Enhancement Award from the Department of Veterans Affairs.

Abbreviations: BSAP, Bone-specific alkaline phosphatase; DPD, deoxypyridinoline cross-links; GIOP, glucocorticoid-induced osteoporosis; hPTH, human PTH; HRT, hormone replacement therapy; IL-6sR, IL-6 soluble receptor; OC, osteocalcin; OPG, osteoprotegrin; RANK, receptor activator of nuclear factor-B; RANKL, RANK ligand; sRANKL, soluble RANKL.

This article has been cited by other articles:

				A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]

				A. D Anastasilakis, D. G Goulis, S. A Polyzos, S. Gerou, V. Pavlidou, G. Koukoulis, and A. Avramidis Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-{kappa}B ligand levels in women with established osteoporosis treated with teriparatide Eur. J. Endocrinol., March 1, 2008; 158(3): 411 - 415. [Abstract] [Full Text] [PDF]

				I. A. Nakchbandi, R. Lang, B. Kinder, and K. L. Insogna The Role of the Receptor Activator of Nuclear Factor-{kappa}B Ligand/Osteoprotegerin Cytokine System in Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 967 - 973. [Abstract] [Full Text] [PDF]

				H. R. Johansson, R. Skripitz, and P. Aspenberg Bisphosphonates can block the deterioration in implant fixation after withdrawal of intermittent doses of parathyroid hormone J Bone Joint Surg Br, March 1, 2008; 90-B(3): 400 - 404. [Abstract] [Full Text] [PDF]

				F. Joseph, B. Y. Chan, B. H. Durham, A. M. Ahmad, S. Vinjamuri, J. A. Gallagher, J. P. Vora, and W. D. Fraser The Circadian Rhythm of Osteoprotegerin and Its Association with Parathyroid Hormone Secretion J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3230 - 3238. [Abstract] [Full Text] [PDF]

				J. Cunningham Pathogenesis and Prevention of Bone Loss in Patients Who Have Kidney Disease and Receive Long-Term Immunosuppression J. Am. Soc. Nephrol., January 1, 2007; 18(1): 223 - 234. [Abstract] [Full Text] [PDF]

				A. Rogers and R. Eastell Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor {kappa}B Ligand: Clinical Utility in Metabolic Bone Disease Assessment J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6323 - 6331. [Abstract] [Full Text] [PDF]

				Y. Iwasaki-Ishizuka, H. Yamato, T. Nii-Kono, K. Kurokawa, and M. Fukagawa Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone Nephrol. Dial. Transplant., September 1, 2005; 20(9): 1904 - 1911. [Abstract] [Full Text] [PDF]

				S. V. Komarova Mathematical Model of Paracrine Interactions between Osteoclasts and Osteoblasts Predicts Anabolic Action of Parathyroid Hormone on Bone Endocrinology, August 1, 2005; 146(8): 3589 - 3595. [Abstract] [Full Text] [PDF]